The BIVDA Market Audit results for the first half of 2025 have been released to participating companies.
The market audit shows strong growth in some areas versus 2024, with over 6% growth overall and over 7% without Coronavirus testing or diabetes management rapid testing (DMRT).
Some disciplines continue to decline, however. The total value recorded is over £1.2bn covering 25 of the largest companies and estimated to be 95% of the total excluding DMRT. A figure including the DRMT (which is reported in government prescription data) will be included in the summary report at the end of the year.
